Katherine Juang is an associate partner at the firm's Corporate and Investment Department and is a core member of the Healthcare & Life Sciences practice groups.
Katherine brings extensive experience in providing comprehensive legal services to clients in the health and life science sector. Her expertise includes legal consultation on risk management and compliance regarding transactions and interaction with health care providers, regulatory matters, data protection, promotional activities, general code of conduct, market access, and negotiation and remedy in reimbursement price disputes. In response to recent developments, Katherine has supported clients in developing strategies to address the evolving landscape of digital health, precision health, and regenerative medicine. She has also represented numerous multinational pharmaceutical companies in patent litigation, unfair competition claims, IP collaboration and licensing negotiations, and patent term extension disputes.
Healthcare & Life Sciences; Data Privacy; Competition Law; Intellectual Property; Product Law; Dispute Resolution
Group Leader, Healthcare Law Group, Legislation Advisory Committee, Taipei Bar Association
Courses Planning Counselor, Graduate Institute of Health and Biotechnology Law, TMU
Lecturer, Graduate Institute of Health and Biotechnology Law, TMU
Counselor, GMO Food Counselors Commission, Taiwan FDA
Board Director, Taiwan Society for Biopreservation and Biobanking
R.O.C. arbitrator (2019)
Admitted to Taiwan Bar Association (2002)
2024 |
Healthcare: Medical Devices 2024|Taiwan
Chambers Global Practice Guides: Healthcare: Medical Devices 2024 |
2024 |
President announces regenerative medicine dual legislation, opening a new chapter in the quality of regenerative medicine and patient rights
LEXOLOGY |
2024 |
Lexology In-Depth: Life Sciences Law | Taiwan Lexology In-Depth: Life Sciences Law |
2023 |
Court rules in favour of pharmaceutical companies that market category two new drugs
ILO IP Newsletter (20230424) |
2023 |
Taipei High Administrative Court's Latest Ruling: Patent Information of "Category II New Drugs" Allowed to be Submitted in Patent Linkage Registration System
LEXOLOGY |
2023 | 專題演講:IRPMA Code of Practice 簡介|講師 中華民國開發性製藥研究協會 |
2023 | Regulatory Insights for Regenerative Medicine in Taiwan and Business Shifts | Speaker Lee and Li, Attorneys-at-Law, ERM Taiwan |